Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACTU, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nab-paclitaxel | Cancer | Phase 2 · NCT03678883 | Active not recruiting |
| Losartan | Pancreatic Adenocarcinoma | Phase 2 · NCT05077800 | Active not recruiting |
| Irinotecan | Cancer | Phase 2 · NCT03678883 | Active not recruiting |
| Gemcitabine Hydrochloride | Cancer | Phase 2 · NCT03678883 | Active not recruiting |
| FOLFIRNINOX | Pancreatic Adenocarcinoma | Phase 2 · NCT05077800 | Active not recruiting |
| Elraglusib | Advanced Malignant Solid Tumor | Phase 1/2 · NCT07714395 | Not yet recruiting |
| Doxorubicin | Cancer | Phase 2 · NCT03678883 | Active not recruiting |
| Cytotoxic Chemotherapeutic Agent | Pancreatic Adenocarcinoma | Phase 1 · NCT06896188 | Recruiting |
Also used in these trials (approved or third-party drugs, not ACTU's own candidates): Paclitaxel, Ruxolitinib, Retifanlimab, Pembrolizumab, Lomustine, Docetaxel Anhydrous, Carboplatin, Cyclophosphamide, Temozolomide, Topotecan.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACTU holds $4.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.7M/quarter from operations, an estimated runway of 2.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 87 · High
Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACTU files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Aaron G.L. Fletcher Director, 10% owner · +151,840 options |
Insider | 10,196,456 | 42.46% | 2025-06-27 |
| Leslie W. Kreis Director, 10% owner · +121,840 options |
Insider | 10,196,456 | 42.46% | 2025-06-27 |
| Bios Equity COF, LP Director, 10% owner · +121,840 options |
Insider | 10,196,456 | 42.46% | 2025-06-27 |
| Todd S Thomson Director, 10% owner · +45,000 options |
Insider | 2,354,344 | 9.80% | 2026-01-05 |
| Voss Capital, LP | 5%+ holder (13G) | 1,814,263 | 7.55% | 2026-03-31 |
| Daniel M Schmitt President, CEO and Director, Director · +441,285 options |
Insider | 932,456 | 3.88% | 2026-08-14 |
| Bios 2024 Co-Invest, LP Director |
Insider | 125,000 | 0.52% | 2024-08-14 |
Share count 24,014,202 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACTU and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →